Draft:Finjuve

  • Comment: Two citations are to nonexistent DOIs, one DOI resolves to a paper on an unrelated topic. The author spent no time or effort on this, so we shouldn't either. WeirdNAnnoyed (talk) 13:31, 7 February 2026 (UTC)
  • Comment: Suspecting AI use based on total lack of blue links —pythoncoder (talk | contribs) 15:56, 4 February 2026 (UTC)

Finjuve is a topical pharmaceutical formulation of finasteride used in the treatment of androgenetic alopecia (pattern hair loss) in men. It is applied directly to the scalp and is intended to reduce local dihydrotestosterone (DHT) levels while limiting systemic exposure compared with oral finasteride.

Medical use

Finjuve is used in the management of androgenetic alopecia, a common form of hair loss characterised by progressive miniaturisation of scalp hair follicles in genetically predisposed individuals. Finasteride acts by inhibiting 5α-reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT), a key androgen involved in the pathophysiology of androgenetic alopecia.[1]

Topical finasteride formulations have been investigated as an alternative to oral administration in order to concentrate pharmacological activity at the scalp while reducing systemic absorption.[2]

Formulation

Finjuve is formulated for topical application to the scalp and contains finasteride as the active pharmaceutical ingredient. Topical finasteride formulations are designed to enhance delivery of the drug to hair follicles while limiting systemic distribution.

The formulation does not require oral ingestion and is intended for regular cutaneous use as directed by a healthcare professional.

Pharmacology

Finasteride is a selective inhibitor of type II 5α-reductase. By inhibiting this enzyme in scalp tissue, finasteride reduces local concentrations of dihydrotestosterone, which may slow or halt the progression of hair follicle miniaturisation in androgenetic alopecia.[3]

Clinical studies have demonstrated that topical finasteride can significantly reduce scalp DHT levels with substantially lower systemic exposure than oral finasteride.[2]

Regulatory status

Finjuve is licensed as a medicinal product in the United Kingdom. Its regulatory classification and availability vary by jurisdiction and may be subject to prescription-only controls under national medicines regulations.

Finasteride is regulated as a prescription medicine in many countries due to its hormonal mechanism of action and potential systemic effects.[4]

Safety

Adverse effects associated with finasteride have been most commonly reported in relation to oral administration and may include sexual dysfunction and mood-related effects in a minority of patients.[5]

Topical finasteride formulations have generally been associated with lower systemic absorption, though long-term safety outcomes continue to be evaluated in clinical studies.[6]

See also

References

  1. ^ Kaufman, KD (1998). "Clinical studies on the effects of finasteride on hair growth in men with androgenetic alopecia". Journal of the American Academy of Dermatology. 39 (4): 578–589. doi:10.1016/S0190-9622(98)70007-6.
  2. ^ a b Caserini, M (2014). "Pharmacokinetics and safety of topical finasteride in subjects with androgenetic alopecia". International Journal of Clinical Pharmacology and Therapeutics. 52 (10): 842–849. doi:10.5414/CP202007.
  3. ^ Drake, L (1999). "The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia". Journal of the American Academy of Dermatology. 41 (4): 550–554. doi:10.1016/S0190-9622(99)70289-0.
  4. ^ "Finasteride: Summary of Product Characteristics". European Medicines Agency. Retrieved 2026-02-04.
  5. ^ Irwig, MS (2011). "Persistent sexual side effects of finasteride: could they be permanent?". Journal of Sexual Medicine. 8 (6): 1747–1753. doi:10.1111/j.1743-6109.2011.02255.x. PMID 21418145.
  6. ^ Rossi, A (2020). "Efficacy and safety of topical finasteride in the treatment of androgenetic alopecia". Dermatologic Therapy. 33 (6): e14145. doi:10.1111/dth.14145. PMID 32767427.{{cite journal}}: CS1 maint: article number as page number (link)

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.